MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nevirapine

CAS No. : 129618-40-2

MCE 站：Nevirapine

产品活性：Nevirapine (BI-RG 587) 是用于研究 HIV/AIDS 的 HIV-1 逆转录酶非核苷抑制剂，K_i 值为 270 μM。

研究领域：Anti-infection

作用靶点：HIV  |  Reverse Transcriptase

In Vitro: Nevirapine itself is an inhibitor of only CYP3A4 at concentrations that are well above those of therapeutic relevance (K_i=270 μM). Nevirapine has been used as a re-differentiation agent to treat cancers in several human cancer models. At all doses (100, 200, 350, 500 μM) tested, nevirapine significantly inhibits cell proliferation after 48 h treatment. At high dose (500 μM), nevirapine significantly increases the percentage of apoptotic cells compared with control. Nevirapine is a potent and selective inhibitor (IC₅₀=10-100 nM) of the replication of a wide variety of HIV-1 strains in several cellular assays.

In Vivo: Nevirapine is available for use in combination with nucleoside HIV-1 reverse transcriptase inhibitors (e.g., zidovudine, didanosine, etc.). Nevirapine has received FDA approval for use in combination with HIV-1 protease inhibitors (e.g., saquinavir, ritonavir, indinavir, etc.). In humans, nevirapine is eliminated primarily in the urine as glucuronide conjugates of 2-, 3-, 8-, and 12-hydroxynevirapine. Nevirapine is completely absorbed in both sexes of mouse, rat, rabbit, monkey, and chimpanzee. Nevirapine is extensively metabolized in both sexes of all animal species studied. Nevirapine (9 mg/kg, 18 mg/kg and 36 mg/kg) shows significant reduction in ulcer severity score and ulcer index as compared to the control

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Doxorubicin hydrochloride  |  Chloroquine  |  5-Fluorouracil  |  Valproic acid  |  (-)-Epigallocatechin Gallate  |  Shikonin  |  Ivermectin  |  Ebselen  |  Kaempferol  |  Flavopiridol  |  Maraviroc  |  Hydroxyurea  |  Dimethyl fumarate  |  Suramin sodium salt  |  Baicalin  |  Probenecid  |  Ritonavir  |  Fasudil Hydrochloride  |  Lopinavir  |  Betulinic acid  |  Lamivudine  |  Rolipram  |  Nelfinavir Mesylate  |  Oltipraz  |  Saquinavir  |  Rottlerin  |  Daidzin  |  Cepharanthine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。